In particular, the research focuses on the use of the uracil auxotrophic carbamoyl phosphate synthase mutant Toxoplasma gondii (CPS) in the treatment of the most aggressive types of cancer: melanoma, pancreatic cancer [53], lung cancer [49, 52], and ovarian cancer [54]. This evidence concerns the gene CAD and ovarian cancer.